secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-068546
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025
--------------------------------------------------------------------------------

- Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.
- Cash of $216.7M; runway extended into Q1 2027 via reduction in preclinical spend and headcount.
- TNG462 Phase 1/2 monotherapy data update expected 2H 2025; registrational study in pancreatic cancer planned for 2026.
- Combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors daraxonrasib and zoldonrasib to begin enrollment Q2 2025.
- TNG456 Phase 1/2 trial for glioblastoma enrollment expected Q2 2025; TNG260 clinical data update expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/0000950170-25-068546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/tngx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-068546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer